Corbus Pharma (CRBP) Misses Q1 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. SPGI
4. USO
5. AAPL
6. DELL
7. NIO
8. ENOV
9. AON
10. A

Go back to Corbus Pharma (CRBP) Misses Q1 EPS by 16c

Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates

May 9, 2019 7:02 AM EDT


Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical candidate CRB-4001 expected to commence clinical studies in 2019Platform of proprietary drug candidates positions Corbus to become the leader in the treatment of inflammatory and fibrotic diseases targeting the endocannabinoid system (ECS) Company to host conference call and webcast today, May 9th at 8:30 a.m. ET

 Norwood, MA, May 09, 2019 (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings,... More